Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

    Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

  • A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  M1nCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDlcWpXOi1{NfMAje69VQ>? M3TheVczKGh? NVv5NppucW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M1i4e|I3OTN5MUC1
Tca8113/CBP  NVX2SldOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPhNoYzNTJ34pEJ{txO MXy3NkBp NFf3cYJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 Ml;tNlYyOzdzMEW=
Tca8113/PYM  MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTzXnZJOi1{NfMAje69VQ>? MXm3NkBp NUXobZE6cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M4rmOlI3OTN5MUC1
SKOV3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYS2NEBu\y:vbB?= NHTH[|QyNTViZB?= MnLtbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlidHnt[UBl\XCnbnTlcpRtgQ>? NXLPWXZlOjZzM{ewOFM>
SKOV3 NUflZo1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvnd2kxNTRizsznM41t M3ewUlI1NzR6L{eyJIg> MW\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 Mo\PNlYyOjV{N{O=
SKOV3 MVjBdI9xfG:|aYOgRZN{[Xl? MX6yJO69\y:vbB?= NGWzU4o1QCCq MnewbY5lfWOnczDhdI9xfG:|aYO= NXjXNJdbOjZzMkWyO|M>
OSA MVTDcI9vd2enbnnjJGF{e2G7 NHn5PWUzNjVxNTFOwG0> NHvRZVNz\XO3bITzJIlvKGyxd3XyJINwdG:weTDmc5Ju[XSrb36gZZMh[2:vcHHy[YQhfG9iZXn0bIVzKEKPSUGgd4lTVkFidILlZZRu\W62 NVW3d3A1OjZzMUC2NlA>
A549 M3nRNGZ2[3Srb36gRZN{[Xl? M3nSfFAwOjVxNUCg{txO NU\uTYtSOjRiaB?= M2q5XYRwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= MlnINlU6OTd|MUe=
H1975 NEfxRY9HfWO2aX;uJGF{e2G7 NYP1R2N[OC9{NT:1NEDPxE1? NF;TSVMzPCCq NHq5fHBld3ewcnXneYxifGW|IH3pVk0zODViZYjwdoV{e2mxbtMg M{nrNFI2QTF5M{G3
A549 NEjQV5lHfWO2aX;uJGF{e2G7 M{PqbFAwOjVxNUCg{txO MXOyOEBp NESzS3V2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? MWmyOVkyPzNzNx?=
H1975 MnO0SpVkfGmxbjDBd5NigQ>? NYHFVFVWOC9{NT:1NEDPxE1? MWeyOEBp M130NpVxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>? MmmwNlU6OTd|MUe=
A549 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWzRlgzPSEQvF2= MY[yOEBp M1XBR4lvcGmkaYTzJINmdGxiZ4Lve5Rp MYmyOVkyPzNzNx?=
H1975 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGyOUDPxE1? NXnkSoVIOjRiaB?= NGD6VYpqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MmLpNlU6OTd|MUe=
MDA-MB-231 NWnmVGluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHhc|cxNTJ{MDFOwIcwdWx? Mon0O|IhcA>? MkDsTWM2OMLiPTC4OkDPxE1? M1e0d|I2QDN5Nkmx
T47D NV7sV3J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3MNE0zOjBizsznM41t M1T5OFczKGh? MVnJR|UxyqB;IES4Mlkh|ryP NX;Q[3ZKOjV6M{e2PVE>
LCTCC MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zjT2lEPTB;Mz645qCKyrWP M3G4WFI2Pzd|MU[3
MCTCC NXPUXGtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPDUlN7UUN3ME2yMljjiIoEtV2= NYDjTpRLOjV5N{OxOlc>
MegTCC NXPsWHhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;sc2hKSzVyPUSuNgKBkcL3TR?= MoThNlU4PzNzNke=
MonoTCC M4izWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXv[YFTUUN3ME21MlbjiIoEtV2= MkfmNlU4PzNzNke=
MCF7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuyNEDPxE1? M4\lNlczKGh? NVm4elRxcW6mdXPld{Bk\WyuIHTlZZRpKG:oIFjQNe6zNWSncHzleIVlKE2FRkegZ4VtdHN? M1Sz[FI2PzZ7MEK1
A-549  M1KyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS0R40xNjVizszN M2joZVI1KGh? Moe3SG1UV8Li NYf6[2dZcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> M3Tx[VI2PzV3Nkmw
A-549  MXvBdI9xfG:|aYOgRZN{[Xl? MXywMlUh|ryP NVvGc5JvPDhiaB?= NGLGPGRFVVORwrC= NVf6PVhre2ixd4Og[YFzdHliYYDvdJRwe2m|IH\lZZR2emW|IHnuZ4x2\GmwZzDicIVj[mmwZzDhcoQh[2i{b33heIlvKGOxbnTlcpNifGmxbh?= Mn[3NlU4PTV4OUC=
A-549  MV\GeYN1cW:wIFHzd4F6 M1ruOVAvPSEQvF2= NH[4OZk1QCCq NFnkcXFFVVORwrC= M1PYcZNpd3e|IHHi[ZJz[W62IH3pZ5JwfHWkdXzlJIRqe3K3cITpc44> MoPONlU4PTV4OUC=
A-549  MYDGeYN1cW:wIFHzd4F6 NGLTUnkxNjVizszN MkLsOFghcA>? MVzEUXNQyqB? M2PyR4lvcGmkaYTzJI9nKGOnbHygcYloemG2aX;uxsA> M1G5eVI2PzV3Nkmw
RMG-1 NHzkbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVywUVFIUUN3ME2yPE45KMLzIEOuOkBu\y:O NH\MVHIzPTd{NkmxNy=>
FN-RMG-1 NEPL[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHxZlVCUUN3ME20NE42KMLzIESuNkBu\y:OCjFOwG0> NGTsVGkzPTd{NkmxNy=>
RMG-1-hFUT NU\0ToZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljRTWM2OD13OD6xJOKyKDJwNDDt[{9N NGTISVUzPTd{NkmxNy=>
FN-RMG-1-hFUT MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTWXIlKSzVyPUGxPE45KMLzIEGzMlghdWdxTB?= MlvjNlU4OjZ7MUO=
CHP-134  M1Ln[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[xJO69VQ>? MnfySG1UV8Li MXTpcohq[mm2czDzbYdvcW[rY3HueEBk\WyuIHfyc5d1cCClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> NV[4fG96OjV4NUi0OlM>
IMR-32 NH;FfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xJO69VQ>? MWLEUXNQyqB? NXzLcWFKcW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz MXyyOVY2QDR4Mx?=
CHP-134  NWrBfY0xTnWldHnvckBCe3OjeR?= NXTBTlVjOTBizszNxsA> NUSyPXd2TE2VT9Mg NIXGdY5qdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? MkH0NlU3PTh2NkO=
IMR-32 NHTvU29HfWO2aX;uJGF{e2G7 M{K5eVExKM7:TdMg MX3EUXNQyqB? MoD5bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> M1:xe|I2PjV6NE[z
A549 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi1NE4zNTRyMECg{txO M2P5[VczKGh? NFPiXJdKSzVyPUGyOkDDuSB3LkCg{txO MnrNNlU3OjV{NEO=
A549/CDDP MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPsNE4zNTRyMECg{txO NGLHUHo4OiCq MmTnTWM2OD1{NEFCpOKyyqB2NT63JO69VQ>? NHLFN20zPTZ{NUK0Ny=>
H460  NHPCfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW5O2EzPCCq M3\tSmROW09? Mlu0TWM2OD15Lkmg{txO NFjocHYzPTV7OUm5OS=>
H460  NUHhcmhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHhbZZsPy57IN88US=> NEnjOo8zPCCq NFjtVI5FVVOR MXvzbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>? NFPT[GwzPTV7OUm5OS=>
NRK-52E MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVO3NuKhcMLi NFvnTG5KSzVyPUGwNEDDuSBzMj65JO69VQ>? NWjITXl7OjV3NkW2NFM>
RGE NF\OWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3KWZVbPzMEoHlCpC=> NHf2O3FKSzVyPUKyJOKyKDdwNDFOwG0> M1S0OVI2PTZ3NkCz
NRK-52E MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXEVnZ1PzMEoHlCpC=> NF;wToRKSzhyPUG3PUDDuSB7LkWg{txO NX\vdJVCOjV3NkW2NFM>
RGE NHTMVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfCOIw4OsLiaNMg MYDJR|gxRTZ|INMxJFcvPCEQvF2= MWiyOVU3PTZyMx?=
SK-OV-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzlO|IhcA>? NVniR|JyUUN3ME2xNFQvQCEQvF2= MYeyOVUzODF|Mh?=
ES-2 NGCxRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHGXWtUPzJiaB?= MYrJR|UxRTF2Lk[g{txO MW[yOVUzODF|Mh?=
OVCAR-8 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXVdJhEPzJiaB?= NGnBZVJKSzVyPUm2MlAh|ryP NXXENoN{OjV3MkCxN|I>
3AO MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK3NkBp Ml3qTWM2OD14Mz60JO69VQ>? MXOyOVUzODF|Mh?=
A2780 M1fxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkOxO|IhcA>? MnrHTWM2OD1zNEWuO{DPxE1? NVXqfmtROjV3MkCxN|I>
SW626 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G2VFczKGh? MX\JR|UxRTl5LkCg{txO M3W1dVI2PTJyMUOy
OVCAR-3 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHxWIE4OiCq MX3JR|UxRTN{Lk[g{txO MVqyOVUzODF|Mh?=
A549 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTvTWM2OD1zNUGuOVYhyrFiNUOuNFYh|ryP NUjVVHpROjV{N{e0OlE>
4T1 M2LLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTh2Lk[yJOKyKDNyLkC1JO69VQpizszN MViyOVI4PzR4MR?=
BALB/3T3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF2LkOwJOKyKDZwNkig{txO M{P3clI2Ojd5NE[x
B16 NYXWNGExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW0NGUxUUN3ME22OE4{OCEEsTC2MlgyKM7:TR?= MlK1NlUzPzd2NkG=
DU 145 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;jUmlEPTB;M{WuNFQhyrFiMUeuOVQh|ryP Mn3RNlUzPzd2NkG=
FaDu NHiwVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>? NEXpN40zPTJ5N{S2NS=>
HCV-29T MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u5NGlEPTB;NEiuOVchyrFiMkKuOFkh|ryP MmHiNlUzPzd2NkG=
HL-60 NV7mW5RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFzLkGwJOKyKDRwNEeg{txO MnnkNlUzPzd2NkG=
HT-29 M3LYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTh7LkG2JOKyKDF6Lki2JO69VQ>? MnPJNlUzPzd2NkG=
H146 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX5WZlFUUN3ME20PU43yrFzMz6xJO69VQ>? Mn\vNlUyOjR{OEK=
H187 NIOxNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3yd413UUN3ME2xNk44yrF{Lkeg{txO NVjPNG45OjVzMkSyPFI>
H128 NXOzOIN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PkPWlEPTB;MUC2MlTDuTlwNjFOwG0> NWnpOpdLOjVzMkSyPFI>
H69 NI\1cHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXsTGNKSzVyPUe2MlnDuTJ5Lkig{txO NXK2Z49OOjVzMkSyPFI>
H209 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDjTWM2OD1{NUiuNeKyQTlwODFOwG0> MnK2NlUyOjR{OEK=
DMS153 NHztU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrtTWM2OD13Nz64xtE6NjJizszN MVKyOVEzPDJ6Mh?=
H526 M{HodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHEbHdjUUN3ME23MlLDuTFwNzFOwG0> MofiNlUyOjR{OEK=
DMS114 NHqyTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P4VWlEPTB;OEWuPOKyOTJwODFOwG0> MmPPNlUyOjR{OEK=
DMS53 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DZTGlEPTB;MUS2MlLDuTN4LkSg{txO NFvybnIzPTF{NEK4Ni=>
HeLa MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[1MVgxKM7:TR?= M4X4NIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> Mk\tNlUyODl|NkC=
MCF-7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLudollPS16MDFOwG0> MkDDbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MlvRNlUyODl|NkC=
MDA-MB-231 M2LkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYW1MVgxKM7:TR?= MXHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NWLwXHBGOjVzMEmzOlA>
CaOV3 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7VeFc4OiCq MkH6TWM2OD16Nj6xJO69VQ>? NEXhbHIzPTB4OEi0PS=>
OVCAR-3 M4fIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm3NkBp M4jZTmlEPTB;MUe5MlUh|ryP NXnndmlUOjVyNki4OFk>
OVCAR-5 NUDUWIdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zCUFczKGh? NXHYSW5KUUN3ME23OU44KM7:TR?= NELZWXEzPTB4OEi0PS=>
SKOV-3 NULQOId6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\4O|IhcA>? MoXrTWM2OD13MESg{txO MlnHNlUxPjh6NEm=
OVCAR-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL5T2ZWPzJiaB?= NEDsendKSzVyPUK5NE43KM7:TR?= MkLDNlUxPjh6NEm=
OVCAR-8 Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUK3NkBp NYHJWpE6UUN3ME22PVAvOiEQvF2= NXnIOIhyOjVyNki4OFk>
MA148 NHfyO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rT[FI1KGh? MnXyTWM2OD16Mz625qCKyrIkgJmxMlQh|rypL33s M13zOVI1QDNzMEmx
A549 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17PNVI1KGh? M3HLNWlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> MW[yOFg{OTB7MR?=
MDA-MB-231 NG\wS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjyOFVIOjRiaB?= MUDJR|UxRTd2OD6w5qCKyrIkgJmxMlEh|rypL33s M{DMdlI1QDNzMEmx
NCI-ADR/RES  M2[3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjDWlRrOjRiaB?= MWTJR|UxRTF5NUOuNQKBkcLz4pEJOE41KM7:Zz;tcC=> MVOyOFg{OTB7MR?=
MA148 NVv0NFZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojwOFghcA>? Ml[0TWM2OD1{OD6x5qCKyrIkgJmxMlAh|rypL33s M2jKWlI1QDNzMEmx
A549 NGHwdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjqRlI4PDhiaB?= NXnOTXBJUUN3ME2xNVgvOOLCidMx5qCKOS5{IN88[{9udA>? NILYSpUzPDh|MUC5NS=>
MDA-MB-231 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfIepI1QCCq NYG3[3RTUUN3ME2xPFMvOOLCidMx5qCKOS5{IDFOwIcwdWx? NIjuR|IzPDh|MUC5NS=>
NCI-ADR/RES  NYr5dGMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf5OFghcA>? MlXBTWM2OD1zOUOuNQKBkcLz4pEJNU46KM7:Zz;tcC=> NFTvco0zPDh|MUC5NS=>
MA148 M2PaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTlXFdbPzJiaB?= M1zGO2lEPTB;MUOuO-KBkcLz4pEJNU4zKM7:Zz;tcC=> NVHCd5VOOjR6M{GwPVE>
A549 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPkXVE4OiCq NU[4dHE3UUN3ME22OE4{6oDLwsJihKkyNjFizsznM41t MmrhNlQ5OzFyOUG=
MDA-MB-231 NYPEfWU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr5XWk4OiCq NVv4SZU5UUN3ME25PU426oDLwsJihKkyNjFizsznM41t NIC0OYMzPDh|MUC5NS=>
NCI-ADR/RES  MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\TO|IhcA>? NYTpdWRSUUN3ME2zO{416oDLwsJihKkyNjdizsznM41t NGHGWXQzPDh|MUC5NS=>
A549 NWnJVoNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom1O|IhcA>? NWDiW3c3TE2VTx?= M4LlWmlEPTB;MUWyMlQxQSEQvF2= M1rXVVI1PzJzM{Kz
NCI-H157 NVWyNoRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\3SWI4OiCq NYXve5NXTE2VTx?= NUDiWGtSUUN3ME24PU46PzdizszN M4PwdFI1PzJzM{Kz
PC9 MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnXWnU4OiCq MkTwS2M2OD15MT62xtE6NjViwsXN MXiyOFYyQDhyOR?=
A549  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PCUVczKGh? M{XVPGdEPTB;MUO2xtE{OS54INM1UeKh MnrwNlQ3OTh6MEm=
PC9 NX:5bW02SXCxcITvd4l{KEG|c3H5 MmKxNVAxKML3TR?= M{XTV|czKGh? NYjnd4J6cW6mdXPld{BieG:ydH;zbZM> MWmyOFYyQDhyOR?=
A549  NHzEVGpCeG:ydH;zbZMhSXO|YYm= MXmxNFAhyrWP MX[3NkBp MVTpcoR2[2W|IHHwc5B1d3Orcx?= Mo\oNlQ3OTh6MEm=
A549 MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoOwNlQhcA>? M33q[mlEOTB;MT60O|Yhdk1? NXPOOFdLOjR|OU[0N|c>
H1299 NHvvOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jYZ|I1KGh? MV3JR|ExRTBwNESzJI5O MVmyOFM6PjR|Nx?=
HCC15 M3rPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PnbFI1KGh? NUPkXZlmUUNzME2wMlM1PiCwTR?= MoLZNlQ{QTZ2M{e=
H157 NGHNWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSyOEBp NInPN|VKSzFyPUCuPFEhdk1? NE\uWlQzPDN7NkSzOy=>
A2780 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF2LkFihKnDueLCiUGuOEDPxE1? MXqyOFIxQTZ7Mx?=
A2780cisR M1vXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvUSJREUUN3ME20PE466oDLwsJihKk{NjlizszN MX2yOFIxQTZ7Mx?=
A2780ZD0473R Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHaTWM2OD14ND625qCKyrIkgJmzMlIh|ryP MmHjNlQzODl4OUO=
SKOV-3 Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPO[2RKSzVyPUSzMlTjiIoEsfMAjVMvQSEQvF2= MnT2NlQzODl4OUO=

... Click to View More Cell Line Experimental Data

In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
water
For best results, use promptly after mixing.
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT02124902 Recruiting Triple Negative Breast Neoplasms Washington University School of Medicine July 7, 2014 Phase 2
NCT02941523 Not yet recruiting Cancer Noxopharm Limited March 6, 2017 Phase 1|Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID